Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors
No significant difference in RFS or OS was observed between CE and TICE overall. However, TICE may offer more benefit to patients with higher-risk disease. Prospective studies are needed to validate these findings.
Authors
- Hooman Ebrahimi (ORCID: https://orcid.org/0000-0001-5939-3185)
- Edward Maldonado (ORCID: https://orcid.org/0000-0002-7018-8462)
- Michael Olufemi Shodiya
- Miguel Zugman (ORCID: https://orcid.org/0000-0002-2181-8405)
- Caspian Oliai (ORCID: https://orcid.org/0000-0002-6368-8557)
- Tamer Adel Othman (ORCID: https://orcid.org/0000-0001-6376-4495)
- Alex Chehrazi‐Raffle (ORCID: https://orcid.org/0000-0001-5205-4527)
- Rasmus T. Hoeg (ORCID: https://orcid.org/0000-0001-5476-3247)
- Samares Pal (ORCID: https://orcid.org/0000-0002-8792-0031)
- Matthew Mei (ORCID: https://orcid.org/0000-0002-1109-6955)
- Rebecca L. Olin (ORCID: https://orcid.org/0000-0002-5060-0384)
- X. Li
- Ali Zhumkhawala
- Tanya Barauskas Dorff (ORCID: https://orcid.org/0000-0001-5990-298X)
- Salvador Jaime‐Casas (ORCID: https://orcid.org/0009-0009-4334-1300)
- Archana Tripathi (ORCID: https://orcid.org/0000-0001-8531-8226)
- Regina Barragán Carrillo
Institutions
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- City of Hope (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105081
- Citations
- 1
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01